Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational ... (and the continued development of a large...)

Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights

Date:5/9/2011

and the continued development of a larger scale XIAFLEX production process.

Selling, general and administrative costs for the quarter ended March 31, 2011 were $43.2 million, compared to $36.1 million in the comparable 2010 period. The increase was primarily due to the addition of the sales and reimbursement field force and infrastructure, and promotional and training activity in support of the launch of XIAFLEX for Dupuytren's in the U.S.

As of March 31, 2011, Auxilium had $130.9 million in cash, cash equivalents and short-term investments, compared to $128.2 million at December 31, 2010.

Conference CallAuxilium will hold a conference call today, May 9, 2011 at 10:00 a.m. ET, to discuss first quarter 2011 results and operational highlights. The presentation slides to be used during the call are now available on the "For Investors" section of the Company's web site under the "Presentations" tab. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously web cast on the "For Investors" section of the Company's web site under the "Events" tab. The conference call will be archived for future review until June 9, 2011.

Conference call details: Date:Monday, May 9, 2011Time:10:00 a.m. ETDial-in (U.S.):866-314-4483Dial-in (International):617-213-8049Web cast:http://www.auxilium.com Passcode:AUXILIUMTo access an audio replay of the call:Access number (U.S.):888-286-8010Access number (International):617-801-6888Replay Passcode #:77302853About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium marke
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results

Post Your Comments:

(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...

(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...

(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering. ...

(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...

Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2 RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3 Bioinformatics Market Worth $7.5 Billion by 2017 2 Bioinformatics Market Worth $7.5 Billion by 2017 3 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3

[0] RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants [0] Bioinformatics Market Worth $7.5 Billion by 2017 [0] Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 [0] Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.

... Eastern Time -, SAN FRANCISCO, Nov. 10 ... corporate progress and financial,results for the quarter ended September ... of significant,achievement and progress and was capped with the ... collaboration not only gives us,access to a world-class partner ...

... Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... announced today top-line data from its,SB-509-601 clinical trial, one of Sangamo,s ... SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration of ...

... Divestitures of Non-Core Product Lines -, HOPKINTON, ... CALP ) today reported third quarter financial,results ... line divestitures: the,sale of its AutoTrace(R) product line ... of its Pharmaceutical Development and Quality Analysis,(PDQ) product ...

Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs

(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...

(Date:6/17/2013)... in patients with severe brain infections in Vietnam. Further ... responsible for the symptoms of disease. , The virus ... 644 patients with severe brain infections in the study, ... the 122 patients with non-infectious brain disorders that were ... system are often fatal and patients who do survive, ...

(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...

Breaking Biology News(10 mins):The secret of DNA methylation 2 New virus isolated from patients with severe brain infections 2 New virus isolated from patients with severe brain infections 3 'Chemical architects' build materials with potential applications in drug delivery and gas storage 2

[0] The secret of DNA methylation [0] New virus isolated from patients with severe brain infections [0] 'Chemical architects' build materials with potential applications in drug delivery and gas storage

... the sun's heat on weather balloons largely accounts for ... dispute over the existence of global warming, according to ... National Oceanic and Atmospheric Administration (NOAA). , The report, ... direct heat of the sun on temperature probes of ...

... times and until our very own day, been considered ... every growing thing in their path. , Until now, ... were predominantly directed by prevailing winds. Now, Hebrew University ... of these grasshoppers ?namely their polarization vision -- provides ...

... Alberta research team has discovered important new information they ... arterial hypertension (PAH)--a deadly form of high blood pressure ... Therapies are currently limited for a disease that can ... years. , The researchers have shown that Survivin, a ...

Cached Biology News:Errors in the measurement of global warming corrected 2 Locusts' built-in 'surface analysis' ability directs them to fly overland 2 Researchers develop gene therapy to reverse pulmonary arterial hypertension 2 Researchers develop gene therapy to reverse pulmonary arterial hypertension 3

Errors in the measurement of global warming corrected Locusts' built-in 'surface analysis' ability directs them to fly overland Researchers develop gene therapy to reverse pulmonary arterial hypertension

Blue Standard is 3-cyano-7-hydroxycoumarin....

Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...

6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...

Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....

Biology Products:

Fluorescent Standards Blue Standard from Invitrogen Fluorescent Standards Cyan Standard from Invitrogen 6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE) from Molecular Probes (Invitrogen)Rabbit Anti-Human ECE1 Polyclonal Antibody, Unconjugated from Atlas Antibodies